PWSA Blog

Update: Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

On April 6, 2026, PWSA | USA received news that Soleno Therapeutics had agreed to be acquired by Neurocrine Biosciences. Today, May 18, 2026, we are following up with an important update: That acquisition is now complete.

A Quick Recap

When the acquisition was first announced, Soleno described it as an exciting development representing the next step in their efforts to bring VYKAT™ XR (diazoxide choline) extended-release tablets, the first and only FDA-approved treatment for hyperphagia in individuals with PWS ages 4 and older, to more patients and families. Neurocrine Biosciences, a well-established biopharmaceutical company with a strong track record in rare and under-addressed conditions, was clear from the start that this acquisition was focused on accelerating growth and expanding access, not cost-cutting.

Soleno also reassured the PWS community early on that their commitment to patients and families remained unchanged, and that individuals would continue to receive the medicines they depend on throughout the transition.

The Acquisition Is Now Official

As of May 18, 2026, Neurocrine Biosciences has officially completed the acquisition of Soleno Therapeutics. VYKAT XR is now part of Neurocrine’s commercial portfolio, alongside other treatments the company markets for rare and complex conditions. Soleno will continue as a wholly owned subsidiary of Neurocrine going forward.

In marking the completion of the acquisition, Neurocrine’s CEO Kyle W. Gano, Ph.D., shared, “Today marks an important advancement in Neurocrine’s mission to deliver life-changing treatments for patients with significant unmet needs. We welcome our Soleno colleagues to Neurocrine and share their deep commitment to the Prader-Willi syndrome community, and we look forward to working together to make VYKAT XR available to more patients and their families.”

What This Means for PWS Families

Hyperphagia remains one of the most debilitating and life-altering aspects of Prader-Willi syndrome, and VYKAT XR’s approval was a landmark moment for our community. With VYKAT XR now in the hands of a larger company with significant commercial resources and infrastructure, there is real potential for broader access and greater awareness of this treatment in the years ahead.

PWSA | USA will continue to monitor this transition closely, advocate on behalf of families, and keep our community informed every step of the way. As always, our priority is ensuring that individuals living with PWS and their families have the information, support, and access they need.

You can read Neurocrine Biosciences’ full press release announcement at the button below.

Share this!

Scroll to top